Metastatic neuroendocrine hepatic tumors - Resection improves survival

Department of Surgery, Radiology, and Medicine, University of Wisconsin, Madison 59792, USA.
Archives of Surgery (Impact Factor: 4.3). 11/2006; 141(10):1000-4; discussion 1005. DOI: 10.1001/archsurg.141.10.1000
Source: PubMed

ABSTRACT The optimal treatment for hepatic metastases from neuroendocrine tumors remains controversial because of the often indolent nature of these tumors. We sought to determine the effect of 3 major treatment modalities including medical therapy, hepatic artery embolization, and surgical resection, ablation, or both in patients with liver-only neuroendocrine metastases, with the hypothesis that surgical treatment is associated with improvement in survival.
Retrospective study.
Tertiary care center.
Patients with metastatic liver-only neuroendocrine tumors were identified from hospital records.
Patients were subdivided into those receiving medical therapy, hepatic artery embolization, or surgical management.
Effect of treatment on survival and palliation of symptoms was analyzed.
From January 1996 through May 2004, 48 patients with liver-only neuroendocrine metastases were identified (median follow-up, 20 months), including 36 carcinoid and 12 islet cell tumors. Seventeen patients were treated conservatively, which consisted of octreotide (n = 7), observation (n = 6), or systemic chemotherapy (n = 4). Hepatic artery embolization was performed in 18 patients. Thirteen patients underwent surgical therapy, including anatomical liver resection (n = 6), ablation (n = 4), or combined resection and ablation (n = 3). No difference was noted in the percentage of liver involved with tumor between the 3 groups. An association of improved survival was noted in patients treated surgically, with a 3-year survival of 83% for patients treated by surgical resection, compared with 31% in patients treated with medical therapy or embolization (P = .01). No difference in palliation of symptoms was noted among the 3 treatment groups (P = .2).
In patients with liver-only neuroendocrine metastases, surgical therapy using resection, ablation, or both is associated with improved survival.

  • [Show abstract] [Hide abstract]
    ABSTRACT: AimsBile salt export pump (BSEP) is a transporter expressed exclusively at hepatic canaliculi and drives bile-salt efflux. Minimal data exist about BSEP expression in tumours. We hypothesized that BSEP immunohistochemistry would be specific for hepatocellular carcinoma (HCC).Methods And ResultsTissue microarrays including 48 HCC, 41 cholangiocarcinomas, and 24 metastatic tumours in liver were immunostained for BSEP. Expression was compared with common markers of hepatocytic differentiation including CD10, HepPar-1, carcinoembryonic antigen, arginase-1, and glypican-3. BSEP expression was assessed in normal tissues. Special attention was given to adrenal gland (normal and neoplasia). BSEP was easy to interpret and showed no background. Canalicular expression was seen in all normal livers, but not in other normal tissue. BSEP was 90% sensitive and 100% specific for HCC (canalicular in 33 of 43 positive cases). The sensitivity of ARG was slightly higher, but specificity was slightly lower (94% for both). HepPar-1 was 90% sensitive and 97% specific. CD10, pCEA, and GPC3 all had lower sensitivity (74%, 81%, 54% respectively).Conclusions In malignant tumours in the liver, BSEP marking was 100% specific and 90% sensitive for HCC. The specificity of BSEP for HCC obviates the need to identify a “canalicular” pattern, which can limit the utility of other canalicular markers.This article is protected by copyright. All rights reserved.
    Histopathology 11/2014; 66(4). DOI:10.1111/his.12601 · 3.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A wide array of ablation technologies, in addition to the progressive sophistication of imaging technologies and percutaneous, laparoscopic, and open surgical techniques, have allowed us to expand treatment options for patients with liver tumors. In this article, technical considerations of chemical and thermal ablations and their application in hepatic oncology are reviewed. Copyright © 2015 Elsevier Inc. All rights reserved.
    Surgical Oncology Clinics of North America 11/2014; 24(1). DOI:10.1016/j.soc.2014.09.003 · 1.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The role of surgical therapy in patients with liver metastases from neuroendocrine tumors (NETs) is unclear. In this study, the results obtained with curative or palliative resection, by reviewing recent literature and performing a meta-analysis, were examined. A systematic review and meta-analysis of observational studies published between January 1990 and October 2013 were performed. Studies that evaluated the different survival between patients treated by curative or palliative surgical resection of hepatic metastases from NETs were considered. The collected studies were evaluated for heterogeneity, publication bias, and quality. To calculate the pooled hazard ratio (HR) estimate and the 95% confidence interval (95% CI), a fixed-effects model was applied. After the literature search, 2,546 studies were found and, among 38 potentially eligible studies, 3 were considered. We did not find a significant longer survival in patients treated with curative surgical resection of hepatic metastases when compared to palliative hepatic resection HR 0.40 (95% CI: 0.14-1.11). In one study, palliative resection of hepatic metastases significantly increased survival when compared to embolization. Curative and also palliative surgery of NETs liver metastases may improve survival outcome. However, further randomized clinical trials are needed to elucidate this argument.